arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Taysha Gene Therapies, Inc.

TSHA

$6.55 ▲ +0.21 (+3.39%) at close

7 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Taysha Gene Therapies, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.1B

Dividend Yield —

Revenue Growth 17.3% ↗

Op. Margin None

ROIC -29.4% ↗

FCF / Share $-0.29 ↗

Trailing P/E —

Price / Book 7.6x

FCF Yield —

Debt / Equity 0.20

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$9.77M

↑ +17.3% —

Net Income Profit after all expenses

$-109.00M

↓ -22.1% —

FCF / Share Free cash flow per share

$-0.29

↑ +10.0% —

Long-Term Debt Long-term obligations

$50.11M

↑ +14.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health →

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	17.3% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+116%)	-46.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-676%)	517.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+6369%)	—	—	—	—
EPS Growth YoY (%)	5.6% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	62.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	74.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	18.5% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-22.1% Weak ↓ Weak Declining Year-over-year change in net income	20.0% Good ↑ Good Improving Year-over-year change in net income	32.8% Excellent ↑ Excellent Improving Year-over-year change in net income	4.9% Caution Caution Year-over-year change in net income	-190.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	10.0% Fair ↓ Fair Declining Year-over-year change in free cash flow	50.7% Excellent → Excellent Stable Year-over-year change in free cash flow	73.3% Excellent Excellent Year-over-year change in free cash flow	29.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	57.5% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	—	-468.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3226%)	—	—	—	—
FCF Margin (%) (%)	—	—	-497.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.51x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-29.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-62.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-49.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-329.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-103.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-13.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-32.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-57.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-41.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-128.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-81.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-16.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-44.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-394%)	-124.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-932%)	-148.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1093%)	—	-183.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1320%)	-23.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-259%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	0.20x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-66%)	0.61x Fair ↓ Fair Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: At sector avg	0.54x Good ↓ Good Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-10%)	40.01x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+6568%)	0.39x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-35%)	—	—
Interest Coverage (x)	-20.47x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-17.32x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-14.49x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-42.77x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-121.34x Weak Weak Operating income divided by interest expense Optimal: > 5x	-1535.79x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-269.66M	$-95.09M	$-103.43M	$-49.91M	$-111.91M	$-251.25M	—
Debt / EBITDA (x)	-0.46x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.49x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.57x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.24x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.22x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.03	$0.03	$0.13	$0.06	—	—	—
Basic EPS, GAAP (USD)	$-0.34	$-0.36	$-0.96	$-3.78	$-4.64	—	—
Free Cash Flow per Share (USD)	$-0.29	$-0.33	$-0.66	$-2.48	$-3.52	—	—
Book Value per Share (USD)	$0.87	$0.35	$0.40	$0.02	$2.48	$6.65	$0.00
Tangible Book Value per Share (USD)	$0.87	$0.35	$0.40	$0.02	$2.48	$6.65	$0.00
Basic Weighted Avg Shares (shares)	319.71M	250.13M	116.12M	43.95M	37.65M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$298.10M	$115.90M	$113.11M	$33.63M	$107.86M	$250.75M	$-135.00K
LT Debt (USD)	$50.11M	$43.94M	$40.51M	$37.97M	$37.19M	—	—
Total Equity (USD)	$246.94M	$71.53M	$74.94M	$949.00K	$95.38M	$251.30M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$9.77M	$8.33M	$15.45M	$2.50M	—	—	—
Depreciation Expense (USD)	$1.15M	$1.25M	$1.37M	$1.17M	$492.00K	$9.00K	—
Net Income, GAAP (USD)	$-109.00M	$-89.30M	$-111.57M	$-166.01M	$-174.52M	$-60.01M	—
Operating Cash Flow (USD)	$-93.09M	$-81.22M	$-73.02M	$-88.39M	$-117.04M	$-30.73M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 27 quarters

Taysha Gene Therapies, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TSHA with peers